$AMRN
AMARIN CORP PLC\UK Stock $amrn

$amrn Overview Financials Valuation SEC Filings Company Website

2013 Q3 Form 10-Q Financial Statement

#000119312513432814 Filed on November 07, 2013

Income Statement

Concept	2013 Q3	2012 Q3
Revenue	$8.403M
YoY Change
Cost Of Revenue	$3.682M
YoY Change
Gross Profit	$4.721M
YoY Change
Gross Profit Margin	56.18%
Selling, General & Admin	$28.27M	$13.40M
YoY Change	111.05%	290.24%
% of Gross Profit	598.9%
Research & Development	$16.82M	$20.91M
YoY Change	-19.57%	247.8%
% of Gross Profit	356.3%
Depreciation & Amortization	$230.0K	$150.0K
YoY Change	53.33%	650.0%
% of Gross Profit	4.87%
Operating Expenses	$45.10M	$34.31M
YoY Change	31.43%	263.22%
Operating Profit	-$40.37M	-$34.31M
YoY Change	17.67%	263.22%
Interest Expense	-$8.441M	-$4.570M
YoY Change	84.7%	-152433.33%
% of Operating Profit
Other Income/Expense, Net	-$302.0K	-$427.0K
YoY Change	-29.27%	623.73%
Pretax Income	-$50.52M	-$22.85M
YoY Change	121.06%	-123.53%
Income Tax	-$1.635M	$3.573M
% Of Pretax Income
Net Earnings	-$48.88M	-$26.43M
YoY Change	84.98%	-127.43%
Net Earnings / Revenue	-581.74%
Basic Earnings Per Share	-$0.29	-$0.18
Diluted Earnings Per Share	-$0.29	-$0.18
COMMON SHARES
Basic Shares Outstanding	170.2M shares	149.2M shares
Diluted Shares Outstanding	170.2M shares	149.2M shares

Balance Sheet

Concept	2013 Q3	2012 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$225.9M	$215.1M
YoY Change	5.02%	70.85%
Cash & Equivalents	$225.9M	$215.1M
Short-Term Investments
Other Short-Term Assets	$3.537M	$4.110M
YoY Change	-13.94%	86.82%
Inventory	$27.08M	$8.989M
Prepaid Expenses
Receivables	$3.721M
Other Receivables	$0.00
Total Short-Term Assets	$262.6M	$228.7M
YoY Change	14.79%	78.57%
LONG-TERM ASSETS
Property, Plant & Equipment	$646.0K	$796.0K
YoY Change	-18.84%	696.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$5.335M	$15.67M
YoY Change	-65.96%	347.77%
Total Long-Term Assets	$31.28M	$26.26M
YoY Change	19.15%	629.33%
TOTAL ASSETS
Total Short-Term Assets	$262.6M	$228.7M
Total Long-Term Assets	$31.28M	$26.26M
Total Assets	$293.8M	$255.0M
YoY Change	15.23%	93.62%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.233M	$13.70M
YoY Change	-54.49%	260.42%
Accrued Expenses	$12.50M	$18.80M
YoY Change	-33.51%	623.08%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$10.90M
YoY Change
Total Short-Term Liabilities	$31.30M	$32.51M
YoY Change	-3.73%	408.0%
LONG-TERM LIABILITIES
Long-Term Debt	$87.32M	$130.8M
YoY Change	-33.23%	21697.17%
Other Long-Term Liabilities	$811.0K	$702.0K
YoY Change	15.53%	-99.55%
Total Long-Term Liabilities	$88.13M	$131.5M
YoY Change	-32.97%	-15.5%
TOTAL LIABILITIES
Total Short-Term Liabilities	$31.30M	$32.51M
Total Long-Term Liabilities	$88.13M	$131.5M
Total Liabilities	$311.5M	$255.0M
YoY Change	22.19%	57.38%
SHAREHOLDERS EQUITY
Retained Earnings	-$898.5M	-$737.1M
YoY Change	21.9%
Common Stock	$881.0M	$737.3M
YoY Change	19.48%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$217.0K	$217.0K
YoY Change	0.0%
Treasury Stock Shares	20.08K shares	20.08K shares
Shareholders Equity	-$17.70M	$38.00K
YoY Change
Total Liabilities & Shareholders Equity	$293.8M	$255.0M
YoY Change	15.23%	93.62%

Cashflow Statement

Concept	2013 Q3	2012 Q3
OPERATING ACTIVITIES
Net Income	-$48.88M	-$26.43M
YoY Change	84.98%	-127.43%
Depreciation, Depletion And Amortization	$230.0K	$150.0K
YoY Change	53.33%	650.0%
Cash From Operating Activities	-$44.84M	-$39.42M
YoY Change	13.75%	376.66%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	-$220.0K
YoY Change	-100.0%	1000.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	-$410.0K
YoY Change	-100.0%	-75.15%
Cash From Investing Activities	$0.00	-$630.0K
YoY Change	-100.0%	-62.28%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	121.3M	4.900M
YoY Change	2375.51%	12.39%
NET CHANGE
Cash From Operating Activities	-44.84M	-39.42M
Cash From Investing Activities	0.000	-630.0K
Cash From Financing Activities	121.3M	4.900M
Net Change In Cash	76.46M	-35.15M
YoY Change	-317.52%	529.93%
FREE CASH FLOW
Cash From Operating Activities	-$44.84M	-$39.42M
Capital Expenditures	$0.00	-$220.0K
Free Cash Flow	-$44.84M	-$39.20M
YoY Change	14.39%	375.15%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2012Q3	us-gaap	Stockholders Equity StockholdersEquity	38000
CY2012Q3	us-gaap	Derivative Liabilities DerivativeLiabilities	90963000
CY2012Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	215110000
CY2013Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	172664013	shares
CY2013Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights	1.44
CY2013Q3	us-gaap	Share Price SharePrice	6.32
CY2013Q3	us-gaap	Treasury Stock Shares TreasuryStockShares	20079	shares
CY2013Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.50
CY2013Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	9816826	shares
CY2013Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	172643934	shares
CY2013Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	87319000
CY2013Q3	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	12548000
CY2013Q3	us-gaap	Interest Payable Current InterestPayableCurrent	10901000
CY2013Q3	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	2077000
CY2013Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2013Q3	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	7200000
CY2013Q3	us-gaap	Liabilities Current LiabilitiesCurrent	31299000
CY2013Q3	us-gaap	Senior Long Term Notes SeniorLongTermNotes	145316000
CY2013Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	6233000
CY2013Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	811000
CY2013Q3	us-gaap	Stockholders Equity StockholdersEquity	-17697000
CY2013Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	739524000
CY2013Q3	us-gaap	Derivative Liabilities DerivativeLiabilities	47193000
CY2013Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-898459000
CY2013Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1617000
CY2013Q3	us-gaap	Liabilities Liabilities	311543000
CY2013Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	754000
CY2013Q3	us-gaap	Common Stock Value CommonStockValue	141455000
CY2013Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	293846000
CY2013Q3	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	1800000
CY2013Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	5335000
CY2013Q3	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	1400000
CY2013Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3721000
CY2013Q3	us-gaap	Inventory Net InventoryNet	27083000
CY2013Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	9283000
CY2013Q3	us-gaap	Deferred Tax Assets Net Current DeferredTaxAssetsNetCurrent	936000
CY2013Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	4993000
CY2013Q3	us-gaap	Treasury Stock Value TreasuryStockValue	217000
CY2013Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	646000
CY2013Q3	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	14433000
CY2013Q3	us-gaap	Assets Assets	293846000
CY2013Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	225885000
CY2013Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	10870000
CY2013Q3	us-gaap	Other Assets Current OtherAssetsCurrent	3537000
CY2013Q3	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	12166000
CY2013Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	11624000
CY2013Q3	us-gaap	Other Inventory Materials Supplies And Merchandise Under Consignment OtherInventoryMaterialsSuppliesAndMerchandiseUnderConsignment	641000
CY2013Q3	us-gaap	Assets Current AssetsCurrent	262562000
CY2013Q3	amrn	Cash Discount Percent CashDiscountPercent	0.02	pure
CY2013Q3	amrn	Excess Fair Value Over Principal Value ExcessFairValueOverPrincipalValue	42400000
CY2011Q4	us-gaap	Stockholders Equity StockholdersEquity	-5962000
CY2011Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	123125000
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	116602000
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	150360933	shares
CY2012Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	20079	shares
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.50
CY2012Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	150340854	shares
CY2012Q4	us-gaap	Interest Payable Current InterestPayableCurrent	2520000
CY2012Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	25202000
CY2012Q4	us-gaap	Senior Long Term Notes SeniorLongTermNotes	134250000
CY2012Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	85153000
CY2012Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	5224000
CY2012Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	17458000
CY2012Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	816000
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	-3997000
CY2012Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	619266000
CY2012Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	69431000
CY2012Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-747643000
CY2012Q4	us-gaap	Embedded Derivative Fair Value Of Embedded Derivative Liability EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability	14600000
CY2012Q4	us-gaap	Liabilities Liabilities	314852000
CY2012Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	269000
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	124597000
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	310855000
CY2012Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4951000
CY2012Q4	us-gaap	Inventory Net InventoryNet	21262000
CY2012Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	326000
CY2012Q4	us-gaap	Deferred Tax Assets Net Current DeferredTaxAssetsNetCurrent	937000
CY2012Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	5465000
CY2012Q4	us-gaap	Treasury Stock Value TreasuryStockValue	217000
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	811000
CY2012Q4	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	8044000
CY2012Q4	us-gaap	Assets Assets	310855000
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	260242000
CY2012Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	11355000
CY2012Q4	us-gaap	Other Assets Current OtherAssetsCurrent	3253000
CY2012Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	15471000
CY2012Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	11624000
CY2012Q4	us-gaap	Assets Current AssetsCurrent	285694000
CY2013Q3	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	121200000
	dei	Trading Symbol TradingSymbol	AMRN
	dei	Entity Registrant Name EntityRegistrantName	AMARIN CORP PLC\UK
	dei	Amendment Flag AmendmentFlag	false
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
	dei	Document Type DocumentType	10-Q
	dei	Document Period End Date DocumentPeriodEndDate	2013-09-30
	dei	Entity Central Index Key EntityCentralIndexKey	0000897448
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	us-gaap	Fair Value Assumptions Expected Volatility Rate FairValueAssumptionsExpectedVolatilityRate	0.91	pure
	us-gaap	Fair Value Assumptions Expected Dividend Rate FairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Derivatives Embedded Derivatives DerivativesEmbeddedDerivatives	<div> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i><u>Long Term Debt Redemption Feature</u></i></b></font></p> <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">The Company’s December 2012 financing agreement with BioPharma Secured Debt Fund II Holdings Cayman, L.P, or BioPharma, contains a redemption feature whereby, upon a change of control, the Company would be required to pay $140 million, less any previously repaid amount, if the change of control occurs on or before December 31, 2013, or required to repay $150 million, less any previously repaid amount, if the change of control event occurs after December 31, 2013. The Company determined this redemption feature to be an embedded derivative, which is carried at fair value and is classified as Level 3 in the fair value hierarchy due to the use of significant unobservable inputs. The fair value of the embedded derivative was calculated using a probability-weighted model incorporating management estimates for potential change in control, and by determining the fair value of the debt with and without the change in control provision included. The difference between the two fair values of the debt was determined to be the fair value of the embedded derivative. At December 31, 2012, the fair value of the derivative was determined to be $14.6 million, and the debt was valued by comparing debt issues of similar companies with (i) terms of between 4.8 and 8.0 years, (ii) coupon rates of between 3.0% and 11.5% and (iii) market yields of between 10.7% and 27.7%. At September 30, 2013, the fair value of the derivative was determined to be $7.2 million, and the debt was valued by comparing debt issues of similar companies with (i) remaining terms of between 3.5 and 4.4 years, (ii) coupon rates of between 9.9% and 12.5% and (iii) market yields of between 10.4% and 25.8%. The Company recognized a gain of $1.4 million and $7.4 million on the change in fair value of this derivative liability for the three and nine months ended September 30, 2013, respectively.</font></p> </div>
	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P16Y9M18D
	us-gaap	Fair Value Assumptions Risk Free Interest Rate FairValueAssumptionsRiskFreeInterestRate	0.001	pure
	us-gaap	Debt Instrument Call Date Earliest DebtInstrumentCallDateEarliest	2017-01-19
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-157255000
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	386000	shares
	us-gaap	Use Of Estimates UseOfEstimates	<div> <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px; MARGIN-LEFT: 2%"> <font style="FONT-FAMILY: Times New Roman" size="2"><b><i><u>Use of Estimates</u></i></b></font></p> <p style="MARGIN-TOP: 6px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2">The preparation of the Company’s consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, or GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Accounting estimates are based on historical experience and other factors that are considered reasonable under the circumstances. Actual results could differ from those estimates. The preparation of the Company’s condensed consolidated financial statements in accordance with GAAP requires management to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates its estimates and judgments and methodologies, including those related to revenue recognition and related allowances, clinical trial expenses, the valuation of inventory, impairment and amortization of intangibles, share-based compensation, income taxes including the valuation allowance for deferred tax assets, valuation of investments and derivative instruments. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates.</font></p> </div>
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.96
	us-gaap	Fair Value Assumptions Expected Term FairValueAssumptionsExpectedTerm	P1Y
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	121206000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	14000
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	1400000
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	21059000
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	627000
	us-gaap	Income Taxes Paid IncomeTaxesPaid	1395000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-838000
	us-gaap	Valuation Allowances And Reserves Charged To Cost And Expense ValuationAllowancesAndReservesChargedToCostAndExpense	7347000
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-26646000
	us-gaap	Excess Tax Benefit From Share Based Compensation Operating Activities ExcessTaxBenefitFromShareBasedCompensationOperatingActivities	966000
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	283000
	us-gaap	Interest Paid InterestPaid	2713000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-162729000
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	17355000
	us-gaap	Interest Paid InterestPaid	5250000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-155643000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3721000
	us-gaap	Net Income Loss NetIncomeLoss	-150816000
	amrn	Stock Issued During Period Shares Stock Warrants Exercised StockIssuedDuringPeriodSharesStockWarrantsExercised	120000	shares
	amrn	Proceeds From Stock Option Exercise And Other ProceedsFromStockOptionExerciseAndOther	600000
	amrn	Significant Assumptions In Market Price Of Stock SignificantAssumptionsInMarketPriceOfStock	0.10	pure
	amrn	Stock Issued During Period Of Stock And Warrants For Services Or Claims StockIssuedDuringPeriodOfStockAndWarrantsForServicesOrClaims	27000
	amrn	Cash Discount Invoice Terms CashDiscountInvoiceTerms	P30D
	amrn	Proceeds From Exercise Of Stock Options And Warrants ProceedsFromExerciseOfStockOptionsAndWarrants	100000
	amrn	Stock Issued During Period Value Stock Warrants Exercised StockIssuedDuringPeriodValueStockWarrantsExercised	120000
	amrn	Proceeds From Stock Options Exercised Gross ProceedsFromStockOptionsExercisedGross	600000
	amrn	Proceeds From Warrant Exercises Gross ProceedsFromWarrantExercisesGross	100000
	amrn	Increase Decrease In Lease Related Liabilities IncreaseDecreaseInLeaseRelatedLiabilities	3000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-78539000
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	3107913	shares
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.19
	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	103885000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	477000
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-68686000
	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	1238000
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	7834000
	us-gaap	Income Taxes Paid IncomeTaxesPaid	697000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-411000
	us-gaap	Revenues Revenues	16245000
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	384000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-149218000
	us-gaap	Gain On Derivative Instruments Pretax GainOnDerivativeInstrumentsPretax	7400000
	us-gaap	Adjustments To Additional Paid In Capital Tax Effect From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation	966000
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-12838000
	us-gaap	Excess Tax Benefit From Share Based Compensation Operating Activities ExcessTaxBenefitFromShareBasedCompensationOperatingActivities	10106000
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	2273000
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	7000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	5821000
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	14170000
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	7813000
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-6389000
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	13232000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	122912000
	us-gaap	Proceeds And Excess Tax Benefit From Sharebased Compensation ProceedsAndExcessTaxBenefitFromSharebasedCompensation	966000
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	179000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-34357000
	us-gaap	Increase Decrease In Accounts Payable And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities	-1714000
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	8381000
	us-gaap	Operating Expenses OperatingExpenses	165463000
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	101502000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-4827000
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	120000
	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions	5270000
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	121206000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	627000
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	485000
	us-gaap	Direct Operating Costs DirectOperatingCosts	8454000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-14000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	56148000
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	27000
	amrn	Weighted Average Number Basic Diluted Shares Outstanding WeightedAverageNumberBasicDilutedSharesOutstanding	157105	shares
	amrn	Product Sales ProductSales	17862000
CY2012Q3	us-gaap	Operating Expenses OperatingExpenses	34310000
CY2012Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	13397000
CY2012Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3573000
CY2012Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	20913000
CY2012Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-4570000
CY2012Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-22853000
CY2012Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-34310000
CY2012Q3	us-gaap	Net Income Loss NetIncomeLoss	-26426000
CY2012Q3	amrn	Weighted Average Number Basic Diluted Shares Outstanding WeightedAverageNumberBasicDilutedSharesOutstanding	149200	shares
	us-gaap	Operating Income Loss OperatingIncomeLoss	-80794000
	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt	22898000
	us-gaap	Adjustments To Additional Paid In Capital Tax Effect From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation	10106000
	us-gaap	Net Income Loss NetIncomeLoss	-168617000
	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	20000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	8989000
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	13344000
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	9365000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	178762000
	us-gaap	Proceeds And Excess Tax Benefit From Sharebased Compensation ProceedsAndExcessTaxBenefitFromSharebasedCompensation	10106000
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	123000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	98508000
	us-gaap	Increase Decrease In Accounts Payable And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities	33075000
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	1094000
	us-gaap	Operating Expenses OperatingExpenses	80794000
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	41059000
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	144316000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	5888000
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	16526000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	7834000
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	108000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1715000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	39735000
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	24000
	amrn	Weighted Average Number Basic Diluted Shares Outstanding WeightedAverageNumberBasicDilutedSharesOutstanding	141947	shares
	amrn	Derivative Liabilities Transferred To Stockholders Equity DerivativeLiabilitiesTransferredToStockholdersEquity	103885000
	amrn	Stock Issued During Period Shares Stock Warrants Exercised StockIssuedDuringPeriodSharesStockWarrantsExercised	10881276	shares
	amrn	Proceeds From Stock Option Exercise And Other ProceedsFromStockOptionExerciseAndOther	7800000
	amrn	Stock Issued During Period Of Stock And Warrants For Services Or Claims StockIssuedDuringPeriodOfStockAndWarrantsForServicesOrClaims	24000
	amrn	Proceeds From Exercise Of Stock Options And Warrants ProceedsFromExerciseOfStockOptionsAndWarrants	16500000
	amrn	Stock Issued During Period Value Stock Warrants Exercised StockIssuedDuringPeriodValueStockWarrantsExercised	16526000
	amrn	Proceeds From Stock Options Exercised Gross ProceedsFromStockOptionsExercisedGross	7900000
	amrn	Proceeds From Warrant Exercises Gross ProceedsFromWarrantExercisesGross	16600000
	amrn	Reclassification Of Derivative Liabilities To Additional Paid In Capital ReclassificationOfDerivativeLiabilitiesToAdditionalPaidInCapital	103885000
	amrn	Increase Decrease In Lease Related Liabilities IncreaseDecreaseInLeaseRelatedLiabilities	-55000
CY2012Q1	us-gaap	Debt Instrument Redemption Price Percentage DebtInstrumentRedemptionPricePercentage	1.00	pure
CY2012	us-gaap	Fair Value Assumptions Expected Volatility Rate FairValueAssumptionsExpectedVolatilityRate	0.95	pure
CY2012	us-gaap	Fair Value Assumptions Expected Dividend Rate FairValueAssumptionsExpectedDividendRate	0	pure
CY2012	us-gaap	Fair Value Assumptions Risk Free Interest Rate FairValueAssumptionsRiskFreeInterestRate	0.0025	pure
CY2012	us-gaap	Fair Value Assumptions Expected Term FairValueAssumptionsExpectedTerm	P1Y9M18D
CY2012Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.18
CY2012Q3	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	16454000
CY2012Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-427000
CY2013Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.29
CY2013Q3	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-1402000
CY2013Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-302000
CY2013Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-8441000
CY2013Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-50519000
CY2013Q3	us-gaap	Revenues Revenues	8403000
CY2013Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-40374000
CY2013Q3	us-gaap	Gain On Derivative Instruments Pretax GainOnDerivativeInstrumentsPretax	1400000
CY2013Q3	us-gaap	Net Income Loss NetIncomeLoss	-48884000
CY2013Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	3682000
CY2013Q3	us-gaap	Operating Expenses OperatingExpenses	48777000
CY2013Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	28274000
CY2013Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1635000
CY2013Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16821000
CY2013Q3	amrn	Weighted Average Number Basic Diluted Shares Outstanding WeightedAverageNumberBasicDilutedSharesOutstanding	170187	shares

Files In Submission

Name	View Source	Status
0001193125-13-432814-index-headers.html	Edgar Link	pending
0001193125-13-432814-index.html	Edgar Link	pending
0001193125-13-432814.txt	Edgar Link	pending
0001193125-13-432814-xbrl.zip	Edgar Link	pending
amrn-20130930.xml	Edgar Link	completed
amrn-20130930.xsd	Edgar Link	pending
amrn-20130930_cal.xml	Edgar Link	unprocessable
amrn-20130930_def.xml	Edgar Link	unprocessable
amrn-20130930_lab.xml	Edgar Link	unprocessable
amrn-20130930_pre.xml	Edgar Link	unprocessable
d595270d10q.htm	Edgar Link	pending
d595270dex311.htm	Edgar Link	pending
d595270dex312.htm	Edgar Link	pending
d595270dex321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AMRN
AMARIN CORP PLC\UK Stock $amrn

2013 Q3 Form 10-Q Financial Statement

#000119312513432814 Filed on November 07, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AMRN AMARIN CORP PLC\UK Stock $amrn

2013 Q3 Form 10-Q Financial Statement

#000119312513432814 Filed on November 07, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AMRN
AMARIN CORP PLC\UK Stock $amrn